Table 3.
Characteristics of Western European Countries Proposed for the Benchmarking of Country-Specific Opioid Availability Data
| Country | DOME (kilograms) | TNO per patient with SHS (morphine equivalents in miligrams) | DOME per patient with SHS (morphine equivalents in miligrams) | DOME%SHSNEED per patient with SHS (%) |
|---|---|---|---|---|
| Austria | 4,543.56 | 2036.41 | 44,257.89 | 2,173.33 |
| Belgium | 3,051.12 | 2,033.92 | 21,253.67 | 1,044.96 |
| Denmark | 1,561.32 | 2,355.70 | 22,583.46 | 958.67 |
| Finland | 704.45 | 1,928.59 | 10,284.67 | 533.27 |
| France | 9,611.72 | 2,049.24 | 10,985.69 | 536.09 |
| Germany | 29,250.40 | 1,965.19 | 23,763.93 | 1,209.24 |
| Greece | 1,338.40 | 2,061.23 | 8,719.55 | 423.03 |
| Iceland | 112.79 | 2,070.44 | 36,452.12 | 1,760.60 |
| Ireland | 681.91 | 2,120.80 | 15,754.23 | 742.84 |
| Italy | 5,993.92 | 1,892.33 | 6,564.11 | 346.88 |
| Luxembourg | 81.22 | 2,175.14 | 14,135.47 | 649.86 |
| Malta | 5.33 | 2,031.29 | 1,192.60 | 58.71 |
| Netherlands | 4,801.84 | 2,105.40 | 22,349.92 | 1,061.55 |
| Norway | 1,222.26 | 2,127.83 | 22,670.62 | 1,065.43 |
| Portugal | 1,363.96 | 1,861.52 | 8,842.06 | 474.99 |
| Spain | 12,033.79 | 1,897.12 | 20,276.25 | 1,068.79 |
| Sweden | 1,970.14 | 2,071.60 | 16,943.07 | 817.87 |
| Switzerland | 2,430.24 | 1,905.68 | 25,661.84 | 1,346.60 |
| United Kingdom | 12,115.11 | 2,233.55 | 15,569.22 | 697.06 |
| Average (19 countries) | 92,873.85 | 2013.25 | 16529.90 | 821.05 |
DOME: Distributed Opioids in Morphine Equivalents procured by a country for retail distribution, medical use, or scientific research; TNO: estimated Total Opioid Need for pain and dyspnea related to SHS; DOME%SHSNEED: percent indicating the extent to which the opioid quantity expressed by DOME is less than, equal to, or more than the TNO; per patient with SHS: values normalized by population with SHS, as determined by the SHS measure.